Monocyte-related markers as predictors of immune checkpoint inhibitor efficacy and immune-related adverse events: a systematic review and meta-analysis

被引:0
作者
Ezdoglian, Aiarpi [1 ]
Tsang-A-Sjoe, Michel [1 ]
Khodadust, Fatemeh [1 ]
Burchell, George [2 ]
Jansen, Gerrit [1 ]
de Gruijl, Tanja [3 ]
Labots, Mariette [4 ]
van der Laken, Conny J. [1 ]
机构
[1] Univ Amsterdam, Dept Rheumatol & Clin Immunol, Med Ctr, Amsterdam, Netherlands
[2] Univ Amsterdam, Med Lib, Amsterdam, Netherlands
[3] Univ Amsterdam, Locat Vrije Univ, Canc Ctr Amsterdam, Dept Med Oncol,Med Ctr, Amsterdam, Netherlands
[4] Univ Amsterdam, Locat Vrije Univ, Dept Med Oncol, Med Ctr, Amsterdam, Netherlands
关键词
Monocytes; Immune checkpoint inhibitors; Immune-related adverse events; M-MDSCs; Monocytic myeloid-derived suppressor cells; PD-1; PD-L1; CTLA-4; CELL LUNG-CANCER; PERIPHERAL-BLOOD BIOMARKERS; TO-LYMPHOCYTE RATIO; CLINICAL-OUTCOMES; LACTATE-DEHYDROGENASE; NIVOLUMAB MONOTHERAPY; IPILIMUMAB; SURVIVAL; CARCINOMA; IMMUNOTHERAPY;
D O I
10.1007/s10555-025-10246-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The efficacy and off-target effects of immune checkpoint inhibitors (ICI) in cancer treatment vary among patients. Monocytes likely contribute to this heterogeneous response due to their crucial role in immune homeostasis. We conducted a systematic review and meta-analysis to evaluate the impact of monocytes on ICI efficacy and immune-related adverse events (irAEs) in patients with cancer. We systematically searched PubMed, Web of Science, and Embase for clinical studies from January 2000 to December 2023. Articles were included if they mentioned cancer, ICI, monocytes, or any monocyte-related terminology. Animal studies and studies where ICIs were combined with other biologics were excluded, except for studies where two ICIs were used. This systematic review was registered with PROSPERO (CRD42023396297) prior to data extraction and analysis. Monocyte-related markers, such as absolute monocyte count (AMC), monocyte/lymphocyte ratio (MLR), specific monocyte subpopulations, and m-MDSCs were assessed in relation to ICI efficacy and safety. Bayesian meta-analysis was conducted for AMC and MLR. The risk of bias assessment was done using the Cochrane-ROBINS-I tool. Out of 5787 studies identified in our search, 155 eligible studies report peripheral blood monocyte-related markers as predictors of response to ICI, and 32 of these studies describe irAEs. Overall, based on 63 studies, a high MLR was a prognostic biomarker for short progression-free survival (PFS) and overall survival (OS) hazard ratio (HR): 1.5 (95% CI: 1.21-1.88) and 1.52 (95% CI:1.13-2.08), respectively. The increased percentage of classical monocytes was an unfavorable predictor of survival, while low baseline rates of monocytic myeloid-derived suppressor cells (m-MDSCs) were favorable. Elevated intermediate monocyte frequencies were associated but not significantly correlated with the development of irAEs. Baseline monocyte phenotyping may serve as a composite biomarker of response to ICI; however, more data is needed regarding irAEs. Monocyte-related variables may aid in risk assessment and treatment decision strategies for patients receiving ICI in terms of both efficacy and safety.
引用
收藏
页数:20
相关论文
共 187 条
  • [1] Immune checkpoint blockade therapy mitigates systemic inflammation and affects cellular FLIP-expressing monocytic myeloid-derived suppressor cells in non-progressor non-small cell lung cancer patients
    Adamo, Annalisa
    Frusteri, Cristina
    Pilotto, Sara
    Caligola, Simone
    Belluomini, Lorenzo
    Poffe, Ornella
    Giacobazzi, Luca
    Dusi, Silvia
    Musiu, Chiara
    Hu, Yushu
    Wang, Tian
    Rizzini, Davide
    Vella, Antonio
    Cane, Stefania
    Sartori, Giulia
    Insolda, Jessica
    Sposito, Marco
    Incani, Ursula Cesta
    Carbone, Carmine
    Piro, Geny
    Pettinella, Francesca
    Qi, Fang
    Wang, Dali
    Sartoris, Silvia
    De Sanctis, Francesco
    Scapini, Patrizia
    Dusi, Stefano
    Cassatella, Marco Antonio
    Bria, Emilio
    Milella, Michele
    Bronte, Vincenzo
    Ugel, Stefano
    [J]. ONCOIMMUNOLOGY, 2023, 12 (01):
  • [2] Prognostic Significance of Hematological Indices in Malignant Melanoma Treated With Immune Checkpoint Inhibitors
    Afzal, Muhammad Z.
    Sarwar, Tayyaba
    Shirai, Keisuke
    [J]. JOURNAL OF IMMUNOTHERAPY, 2019, 42 (07) : 251 - 264
  • [3] Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond
    Ai, Luoyan
    Xu, Antao
    Xu, Jie
    [J]. REGULATION OF CANCER IMMUNE CHECKPOINTS: MOLECULAR AND CELLULAR MECHANISMS AND THERAPY, 2020, 1248 : 33 - 59
  • [4] Immune-Related Adverse Events by Immune Checkpoint Inhibitors Significantly Predict Durable Efficacy Even in Responders with Advanced Non-Small Cell Lung Cancer
    Akamatsu, Hiroaki
    Murakami, Eriko
    Oyanagi, Jun
    Shibaki, Ryota
    Kaki, Takahiro
    Takase, Eri
    Tanaka, Masanori
    Harutani, Yuhei
    Yamagata, Nao
    Okuda, Yuka
    Furuta, Katsuyuki
    Sugimoto, Takeya
    Teraoka, Shunsuke
    Hayata, Atsushi
    Tokudome, Nahomi
    Ozawa, Yuichi
    Mori, Keita
    Koh, Yasuhiro
    Yamamoto, Nobuyuki
    [J]. ONCOLOGIST, 2020, 25 (04) : E679 - E683
  • [5] A high number of PD-L1+CD14+monocytes in peripheral blood is correlated with shorter survival in patients receiving immune checkpoint inhibitors
    Ando, Kiyohiro
    Hamada, Kazuyuki
    Shida, Midori
    Ohkuma, Ryotaro
    Kubota, Yutaro
    Horiike, Atsushi
    Matsui, Hiroto
    Ishiguro, Tomoyuki
    Hirasawa, Yuya
    Ariizumi, Hirotsugu
    Watanabe, Makoto
    Onoue, Rie
    Tsurutani, Junji
    Yoshimura, Kiyoshi
    Tsunoda, Takuya
    Kobayashi, Shinichi
    Wada, Satoshi
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2021, 70 (02) : 337 - 348
  • [6] Immune Cell Profiling of Peripheral Blood as Signature for Response During Checkpoint Inhibition Across Cancer Types
    Araujo B. de Lima, Vinicius
    Hansen, Morten
    Spanggaard, Iben
    Rohrberg, Kristoffer
    Reker Hadrup, Sine
    Lassen, Ulrik
    Svane, Inge Marie
    [J]. FRONTIERS IN ONCOLOGY, 2021, 11
  • [7] Sacroiliitis as an immune-related adverse event of pembrolizumb treatment for melanoma
    Araujo, F. C.
    Afonso, P. D.
    [J]. SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2022, 51 (04) : 342 - 343
  • [8] Correlation of Peripheral Blood Parameters and Immune-Related Adverse Events with the Efficacy of Immune Checkpoint Inhibitors
    Bai, Rilan
    Li, Lingyu
    Chen, Xiao
    Chen, Naifei
    Song, Wei
    Zhang, Yongfei
    Lv, Zheng
    Han, Fujun
    Zhao, Yuguang
    Li, Wei
    Cui, Jiuwei
    [J]. JOURNAL OF ONCOLOGY, 2021, 2021
  • [9] Risk Models for Advanced Melanoma Patients Under Anti-PD-1 Monotherapy-Ad hoc Analyses of Pooled Data From Two Clinical Trials
    Bai, Xue
    Dai, Jie
    Li, Caili
    Cui, Chuanliang
    Mao, Lili
    Wei, Xiaoting
    Sheng, Xinan
    Chi, Zhihong
    Yan, Xieqiao
    Tang, Bixia
    Lian, Bin
    Wang, Xuan
    Zhou, Li
    Li, Siming
    Kong, Yan
    Qi, Zhonghui
    Xu, Huayan
    Duan, Rong
    Guo, Jun
    Si, Lu
    [J]. FRONTIERS IN ONCOLOGY, 2021, 11
  • [10] Differential effects of PD-L1 versus PD-1 blockade on myeloid inflammation in human cancer
    Bar, Noffar
    Costa, Federica
    Das, Rituparna
    Duffy, Alyssa
    Samur, Mehmet
    McCachren, Samuel
    Gettinger, Scott N.
    Neparidze, Natalia
    Parker, Terri L.
    Bailur, Jithendra Kini
    Pendleton, Katherine
    Bajpai, Richa
    Zhang, Lin
    Xu, Mina L.
    Anderson, Tara
    Giuliani, Nicola
    Nooka, Ajay
    Cho, Hearn J.
    Raval, Aparna
    Shanmugam, Mala
    Dhodapkar, Kavita M.
    Dhodapkar, Madhav V.
    [J]. JCI INSIGHT, 2020, 5 (12)